What Is Compulsory Licensing?
Compulsory licensing lets a government allow someone else to make or sell a patented product-like a medicine-without the patent holder’s permission. It doesn’t take away the patent. The company still owns it. But the government says, "We need this now, and you’re not making enough or charging too much. So here’s someone else who can produce it, and you’ll get paid."
This isn’t some secret loophole. It’s written into international law. The TRIPS Agreement is the global rulebook on intellectual property, created by the World Trade Organization in 1994. Article 31 of TRIPS says countries can issue compulsory licenses under certain conditions, especially when public health is at risk. It’s not about stealing. It’s about balance. Patents exist to reward innovation, but they shouldn’t block access to life-saving drugs.
When Is It Used?
Most compulsory licenses happen in emergencies. Think pandemics, epidemics, or when a medicine is priced so high that no one can afford it.
During the HIV/AIDS crisis in the early 2000s, South Africa, Brazil, and Thailand used compulsory licensing to bring down the cost of antiretroviral drugs. In one case, Brazil cut the price of efavirenz from $1.55 per tablet to $0.48. Thailand slashed the annual cost of lopinavir/ritonavir from $1,200 to $230. These weren’t random decisions. They were responses to tens of thousands of deaths that could have been prevented.
The same thing happened during COVID-19. Over 40 countries, including Germany, Canada, and Israel, prepared to issue compulsory licenses for vaccines and treatments. Some actually did. Spain passed a law in 2020 allowing emergency licenses without first asking the patent holder. That’s the "extreme urgency" exception in TRIPS-when waiting for negotiations could cost lives.
How Does It Work in Different Countries?
Not every country uses compulsory licensing the same way. The rules vary, and so does the frequency.
India has been the most active. Since 2005, it has issued 22 compulsory licenses, almost all for cancer drugs. The most famous case was Nexavar, a kidney and liver cancer drug made by Bayer. The Indian government allowed Natco Pharma to make a generic version. Bayer got paid 6% of net sales-a formula set by the courts. The price dropped from $5,500 per month to $175. That’s what access looks like.
United States rarely uses it. The main legal tool is Section 1498 of Title 28 of the U.S. Code, which lets the federal government use any patented invention for its own purposes, like military or public health needs, as long as it pays compensation. But it’s rarely used outside government contracts. The government has issued fewer than 10 since 1945. There’s also Bayh-Dole Act march-in rights, which allow the government to force licensing of drugs developed with federal funding if they’re not being made available to the public. The NIH has received 12 petitions for march-in rights since 1980-and denied every single one, saying the company was "doing enough."
Germany has the legal power under its Patent Act to issue licenses for public interest, but it has never done so. Canada used its compulsory licensing law only once-in 2012-to send HIV drugs to Rwanda. That was made possible by a special WTO rule that lets countries without drug factories import generics made under license.
What Are the Rules?
TRIPS sets the baseline. Here’s what’s required:
- The government must try to get a voluntary license first (negotiate with the patent holder).
- But if it’s an emergency, like a pandemic, that step can be skipped.
- The license must be mostly for the country’s own use-not to export (unless under the special waiver).
- The patent holder must get "adequate remuneration." That’s not a fixed number. It’s based on the value of the invention.
- The license can’t be exclusive. Others can also get it.
Some countries add more. India requires the applicant to prove they can actually make the drug. The U.S. requires lawsuits in the Court of Federal Claims. Canada requires a formal declaration of public health need. The process isn’t easy. It takes time, legal expertise, and political will.
Who Benefits-and Who Loses?
The biggest winners are patients. In low- and middle-income countries, compulsory licensing has cut the price of first-line HIV drugs by 92% since 2000. Generic manufacturers like Teva Pharmaceuticals have earned over $3 billion in additional revenue from these markets between 2015 and 2020. Governments save billions in public health spending. People live.
Who loses? Mostly, it’s the pharmaceutical companies. A 2018 study in the Journal of Health Economics found that countries with active compulsory licensing saw a 15-20% drop in pharmaceutical R&D investment. When a company announces its drug might be licensed, its stock often falls by 8.2%, according to the IFPMA International Federation of Pharmaceutical Manufacturers & Associations. That’s real money. That’s fear.
But here’s the twist: the threat of compulsory licensing often works better than the actual license. Professor Brook Baker found that since 2000, 90% of HIV drug price cuts in developing countries happened because companies voluntarily lowered prices-just to avoid a license. That’s leverage. That’s power.
Controversies and Criticisms
Some argue compulsory licensing kills innovation. If companies can’t profit, why invest in new drugs? That’s a valid concern. But the data doesn’t support the fear. Between 1995 and 2020, only 70 compulsory licenses were issued for medicines worldwide. That’s less than four per year. Meanwhile, global pharmaceutical R&D spending has tripled in the same period.
Others say the process is too slow. In India, the legal battle over Nexavar took eight years. By then, the drug was already on the market. In the U.S., Section 1498 cases take an average of 2.7 years to resolve. That’s too long for a pandemic.
There’s also the issue of capacity. The WHO says 60% of low-income countries don’t have the legal or technical staff to even start the process. Without trained patent lawyers, public health officials, and drug regulators, the law is just words on paper.
What’s Changing Now?
The world is shifting. In June 2022, the WTO agreed to a temporary waiver on COVID-19 vaccine patents. It lets developing countries produce vaccines without permission until 2027. But only 12 factories in 8 countries have actually started using it. Why? Because it’s complicated. You need raw materials, technical know-how, regulatory approval, and funding. A license doesn’t automatically mean production.
The European Union is pushing new rules. Its 2023 Pharmaceutical Strategy says patent holders must offer licensing terms within 30 days-or face automatic compulsory licensing. That’s a game-changer. It flips the script. Instead of waiting for a crisis, governments can act faster.
And there’s a new global push: the WHO’s draft Pandemic Treaty. Article 12 proposes automatic compulsory licensing for essential health products during any declared public health emergency. No negotiations. No delays. Just access.
Is This the Future?
Compulsory licensing isn’t going away. It’s becoming more targeted. Experts predict that by 2030, 75% of licenses will be limited to emergencies, specific diseases, or public health threats-not general market complaints.
The real question isn’t whether governments should have this power. It’s whether they’ll use it wisely. The tools are there. The laws exist. The evidence shows it saves lives. What’s missing is the political courage to act before it’s too late.
Dec 4, 2025 — Gillian Watson says :
This is one of those topics where the math is simple but the politics are messy. People die because a drug costs more than a car. That’s not capitalism, that’s failure.
Simple as that.